Hutchison China Meditech Limited (HCM)

 

Latest News

Total Voting Rights

RNS Number: 6992J Hutchison China Meditech Limited 30 June 2017 Total Voting Rights London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shares of US$1.00 each, with ea...

Chi-Med and AZ start global trial of renal cancer drug

Hutchison China MediTech and AstraZeneca have initiated a global pivotal phase III, open-label, randomised multi-centre r...

Blocklisting Six Monthly Return

RNS Number: 4737J Hutchison China Meditech Limited 29 June 2017 Blocklisting Six Monthly Return London: Thursday, June 29 , 201 7: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutchison China Medi...

Start of Savolitinib Global PRCC Phase III Trial

RNS Number: 5372J Hutchison China Meditech Limited 29 June 2017 Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma London: Thursday, June 29, 2017: Chi-Med and AstraZeneca today announce that they have initiated a global pivotal Phase III, open-label, randomized multi-center registration study...

All News

DateHeadlineSource
30-06-17Total Voting RightsRNS
29-06-17Chi-Med and AZ start global trial of renal cancer drug StockMarketWire
29-06-17Blocklisting Six Monthly ReturnRNS
29-06-17Start of Savolitinib Global PRCC Phase III TrialRNS
29-06-17Chi-Med to Announce 2017 HY Financial ResultsRNS
22-06-17Chi-Med starts clinical trial in China StockMarketWire
22-06-17Chi-Med starts Ph I/II Trial of HMPL 453 in ChinaRNS
16-06-17Director's Share DealingRNS
12-06-17Fruquintinib NDA for Advanced CRC Filed with CFDARNS
06-06-17Fruquintinib data highlighted at ASCO, says Chi-MedStockMarketWire
06-06-17Phase III Fruquintinib Data presented at ASCORNS
02-06-1712 AIM shares in the 1,000% clubInteractive Investor
18-05-17Broker Forecast - Panmure Gordon issues a broker note on Hutchison China Meditech LtdStockMarketWire
18-05-17Chi-Med Presents Clinical Data at ASCO 2017RNS
28-04-17Total Voting RightsRNS
27-04-17Results of Annual General MeetingRNS
13-04-17Why Shell was kicked out of this top-performing portfolioInteractive Investor
07-04-17Chi-Med present pre-clinical data at AACRStockMarketWire
07-04-17Pre-clinical Data Presented at AACRRNS
31-03-17Total Voting RightsRNS
29-03-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
29-03-17Vesting of LTIP awardsRNS
28-03-17Grant of Share Options under Share Option SchemeRNS
27-03-172016 Annual Report and Notice of AGMRNS
24-03-17Chi-Med chief scientific officer joins board StockMarketWire
24-03-17Appointment of DirectorRNS
21-03-17Chi-Med to host R&D BriefingsRNS
20-03-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
20-03-17Directors' Share DealingRNS
16-03-17Grant of Awards under Long Term Incentive PlanRNS
13-03-17Hutchison China MediTech shares tipped to hit record highInteractive Investor
13-03-17Higher commodity prices boost FTSE as May considers triggering Article 50StockMarketWire
13-03-17Record revenues and net income at Chi-Med StockMarketWire
13-03-17Publication of Form 20-FRNS
13-03-17Final ResultsRNS
10-03-17Chi-Med presents pre-clinical data at ENETSStockMarketWire
10-03-17Sulfatinib Phase Ib/II Results Presented at ENETSRNS
10-03-17Sulfatinib Phase Ib/II Results Presented at ENETSRNS
03-03-17Chi-Med reveals positive results from cancer drug trial StockMarketWire
03-03-17Positive Fruquintinib Pivotal Phase III ResultsRNS

RSS feeds

  • Editorial news feed for LSE:HCM Editorial
  • Regulatory news feed for LSE:HCM Regulatory